Display options
Share it on

Oncol Lett. 2017 Jul;14(1):918-924. doi: 10.3892/ol.2017.6262. Epub 2017 May 26.

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer.

Oncology letters

Keiichi Ito, Shigeyoshi Soga, Kenji Seguchi, Yusuke Shinchi, Ayako Masunaga, Shinsuke Tasaki, Kenji Kuroda, Akinori Sato, Junichi Asakuma, Akio Horiguchi, Hiroshi Shinmoto, Tatsumi Kaji, Tomohiko Asano

Affiliations

  1. Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
  2. Department of Radiology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.

PMID: 28693252 PMCID: PMC5494732 DOI: 10.3892/ol.2017.6262

Abstract

Partial nephrectomy is the treatment of choice for small renal cell carcinoma (RCC) from the perspective of cancer management and renal function. However, when patients with RCC are of advanced age, exhibit severe comorbidities, including cardiovascular and pulmonary diseases, or have hereditary RCC, ablative therapies, including radiofrequency ablation (RFA) and cryoablation are useful treatment options. In the present study, the clinical outcomes of percutaneous RFA for treating small RCC were evaluated. Between December 2005 and March 2015, 40 patients (41 renal tumors in total) underwent RFA and a total of 50 sessions of RFA were performed. The average tumor size was 2.5 cm. A total of 18 tumors were exophytic and 23 were parenchymal. Of the 41 tumors, 85.4% were completely ablated by initial RFA and the rate of complete ablation following reablation for residual viable lesions was 95.1%. Local recurrence-free survival following complete ablation was 84.2% at 3 years. A patient with a 4.7 cm RCC tumor rapidly progressed following four RFA treatments until complete ablation was achieved. The metastasis-free survival rate following initial RFA was 95.7% at 3 years. The RCC-specific survival was 100% (mean follow-up, 38 months). Adverse events occurred in five sessions (10%); however, only 1 patient with arteriovenous fistula required intervention (transarterial embolization). The mean hospital stay following RFA was 3.2 days. The mean decrease in estimated glomerular filtration rate following RFA was 2.7%. The results of the present study indicate that percutaneous RFA was an effective treatment for small RCCs with respect to management of cancer, minimal invasiveness and minimal loss of renal function, particularly in patients for whom surgery would be a high risk and those at increased risk of deterioration of renal function.

Keywords: clinical outcome; radiofrequency ablation; rapid progression; renal cell carcinoma; small renal cancer

References

  1. Eur J Radiol. 2010 Mar;73(3):652-6 - PubMed
  2. World J Gastroenterol. 2004 Apr 15;10(8):1137-40 - PubMed
  3. Urology. 2006 Nov;68(5):968-71 - PubMed
  4. BJU Int. 2010 Feb;105(4):496-500 - PubMed
  5. Eur J Gastroenterol Hepatol. 2001 Mar;13(3):291-4 - PubMed
  6. BJU Int. 2006 Apr;97(4):703-5 - PubMed
  7. BJU Int. 2014 Mar;113(3):416-28 - PubMed
  8. Eur Urol. 2007 Mar;51(3):614-20 - PubMed
  9. Eur Urol. 2004 Jun;45(6):692-705 - PubMed
  10. BJU Int. 2012 Sep;110(6 Pt B):E281-6 - PubMed
  11. Curr Opin Urol. 2014 Sep;24(5):466-73 - PubMed
  12. Scand J Urol Nephrol. 2011 Feb;45(1):24-9 - PubMed
  13. Urology. 2012 Jul;80(1):119-24 - PubMed
  14. Urol Oncol. 2014 Oct;32(7):1024-30 - PubMed
  15. Eur Urol. 2004 Apr;45(4):490-3; discussion 493-4 - PubMed
  16. J Endourol. 2010 Dec;24(12 ):1909-13 - PubMed
  17. Eur J Radiol. 2012 Oct;81(10):2730-6 - PubMed
  18. Hepatol Int. 2008 Mar;2(1):116-23 - PubMed
  19. BJU Int. 2009 Apr;103(7):894-8 - PubMed
  20. J Urol. 1995 Jun;153(6):1812-6 - PubMed
  21. J Urol. 2009 Sep;182(3):844-53 - PubMed
  22. J Urol. 2008 Jan;179(1):75-9; discussion 79-80 - PubMed
  23. Cancer. 2010 Jul 1;116(13):3135-42 - PubMed
  24. Cancer. 2009 Apr 1;115(7):1465-71 - PubMed
  25. Lancet Oncol. 2006 Sep;7(9):735-40 - PubMed
  26. BJU Int. 2014 Jan;113(1):51-5 - PubMed
  27. J Endourol. 2014 Mar;28(3):330-4 - PubMed
  28. J Clin Oncol. 1999 Sep;17(9):2868-75 - PubMed
  29. J Transl Med. 2013 Oct 29;11:273 - PubMed
  30. Eur Urol. 2013 Mar;63(3):486-92 - PubMed
  31. J Urol. 2013 Jan;189(1):30-5 - PubMed
  32. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6328S-34S - PubMed
  33. J Urol. 2004 Jan;171(1):120-5 - PubMed
  34. Eur Urol. 2012 Jun;61(6):1156-61 - PubMed

Publication Types